Objectives -To determine whether dexamethasone 'matures' the phospha-
With the emphasis in neonatal intensive care moving towards concerns about morbidity, rather than just mortality, the problem of neonatal chronic lung disease (CLD) is increasing in importance. Neither treatment nor efforts aimed at the prevention of CLD have proved to be completely effective. One of the few treatments which has been shown to work, albeit probably only in the short term, is the use of the corticosteroid dexamethasone.1-4 Little is known about dexamethasone's mechanism of action in the treatment of CLD, and its use is fraught with concerns over side effects.5 Despite this, there is increasing use of dexamethasone earlier in the course of respiratory distress syndrome and CLD,6 and a multicentre trial is currently being planned to study the effects of dexamethasone within 72 hours of life.5
There is a lag of between 24 and 72 hours from the onset of administration of dexamethasone and the beginning of both clinical and physiological improvement in infants with CLD.1-4 Any mechanism proposed to explain the action of dexamethasone in CLD must account both for this delay, and also account for the physiological changes themselves, namely improvements in pulmonary compliance and resistance.7 8 One mechanism that would fulfil both of these criteria is the induction of enzyme systems responsible for the synthesis of pulmonary surfactant. It has been shown conclusively that antenatal steroids will reduce the incidence of respiratory distress syndrome,9 and that this must be due, at least in part, to the improved synthesis and/or secretion ofpulmonary surfactant in the infant.
The saturated phosphatidylcholine (PC) species dipalmitoylphosphatidylcholine (DPPC) is the major surface active component, in vivo, of pulmonary surfactant. We have shown previously that infants who developed respiratory distress syndrome had a lower percentage of DPPC in the PC content of tracheal aspirates taken at birth, and a lower ratio of DPPC to the more unsaturated PC species palmitoyloleoylphosphatidylcholine (POPC) than infants who did not develop respiratory distress syndrome.'0 This difference appeared to be independent of gestational age. We postulated that the higher percentage of DPPC and the higher ratio of DPPC to POPC (the DPPC:POPC ratio) in the infants who did not develop respiratory distress syndrome represented a 'maturation' of the PC composition of pulmonary surfactant, producing a surfactant which was more effective in reducing surface tension and was at least to some extent the reason why Surifactant phosphatidylcholine composition during dexamethasone treatment in chronic lung disease ) . 'Dry' suction of the endotracheal tube only was performed initially. The infants were then positioned supine with their heads turned towards the left. The infants were disconnected from the ventilator, and the first of the preloaded 5 FG catheters introduced into the endotracheal tube, until it was wedged. The saline was then flushed through the catheter, and the ventilator reconnected, with the catheter left in situ. The saline was allowed to dwell for 20 seconds before the ventilator was disconnected again and the saline suctioned out via a modified sputum trap (Unoplast). The catheter was then withdrawn and the ventilator reconnected. The infants were allowed to recover for two minutes, and then the procedure was repeated using the second preloaded syringe and the same sputum trap. Once the lavage was complete, ventilator settings were returned to their original levels. The broncheoalveolar lavage fluid was placed immediately onto ice until centrifuged at 1000 g for 10 minutes, at 40C, to remove cells and cellular debris. The supernatants were aliquoted and stored at -700C, until analysis.
Total lipids were extracted with chloroform:methanol, as described previously. 12 Individual molecular species of PC were resolved by isocratic reverse phase high performance liquid chromatography. Approval for the study was granted by local ethics committees.
Results
Nineteen infants fulfilled the entry criteria during the study period. Consent was declined for one, and the clinician in charge considered that two were too ill to be randomised. Sixteen infants were recruited; eight received dexamethasone and eight placebo. The demographic data are shown in table 1. There were no significant differences between the groups for gestational age, birth weight, or the age at which treatment started. One infant who was randomised to receive dexamethasone was withdrawn from the study on day 6 and restarted on dexamethasone because of a failure to respond. Four infants in the placebo group were withdrawn from the study: two during day 4, one during day 5, and one during day 7 (a total of four out of eight withdrawn) because of a deteriorating clinical condition. All four subsequently received unblinded dexamethasone. Two infants from the dexamethasone group were successfully extubated during day 3. Analysis of the fluid from the 
